Gensight Biologics (LTS:0RIM) Total Deposits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RIM Gensight Biologics SA LTS:0RIM
22 GF Score
Price €0.10
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Gensight Biologics Total Deposits?

Total Deposits only applies to banks.

LTS:0RIM
22GF Score
Gensight Biologics SA LTS:0RIM
Total Deposits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
22GF Score

Get the complete analysis for LTS:0RIM

Total Deposits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price